Overview

Use of Gastrografin in the Management of Fecal Impaction in Patients With Severe Chronic Constipation

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Fecal impaction (FI) is a common cause of lower gastrointestinal tract obstruction, and it is the result of chronic or severe constipation and most commonly found in the elderly population. Gastrografin is a water soluble contrast mediate that could act as an osmotic laxative. It has been shown to confer a therapeutic benefit in adhesive small bowel obstruction (SBO). The investigators speculate that gastrografin administrated orally may be more effective than enema in the treatment of fecal impaction induced intestinal obstruction.
Phase:
Phase 2
Details
Lead Sponsor:
Jinling Hospital, China